DPx Holdings B.V., owned by JLL Partners and Royal DSM, has completed its acquisition of Gallus BioPharmaceuticals, a contract manufacturer specializing in biologics. DPx is the parent company of Patheon, DSM Fine Chemicals and Banner Life Sciences. Following the transaction, Patheon’s biologic drug substance business will have four facilities in Europe, Australia and North America, with 550 employees globally. 
 
Gallus broadens Patheon’s process development capabilities as well as clinical and commercial scale manufacturing of mammalian cell culture derived products. With Gallus’ two sites in St. Louis, MO and Princeton, NJ, Patheon will have its first biologic drug substance sites in the U.S., in addition to its sites in Groningen, the Netherlands and Brisbane, Australia. Patheon will be able to leverage its expertise in disposable technology as well as expand its capabilities in mid-scale flexible manufacturing.  
 
“We are pleased to have closed this transaction within such a short period of time so that we can begin providing customers with an even higher level of service with our expanded service offerings and dedicated biologics presence in the U.S.,” said Jim Mullen, chief executive officer of DPx Holdings. “This acquisition allows us to better serve the biologics segment in our industry and aligns with our strategy to continue to bring our customers an industry leading end-to-end service offering.”
 
Look out for our Newsmakers interview with Manja Bouman of Patheon in the October issue!